| 1. |
- Nordgren, Lars, et al.
(author)
-
Inledning
- 2014
-
In: Health Management. Att leda hälsoverksamheter med service i fokus. - 9789152326671 ; , s. 9-21
-
Book chapter (peer-reviewed)
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
- Andersson, Lena, et al.
(author)
-
Differences between heart failure clinics and primary health care
- 2013
-
In: British Journal of Community Nursing. - London : MA Healthcare Limited. - 1462-4753 .- 2052-2215. ; 18:6, s. 288-292
-
Journal article (peer-reviewed)abstract
- There is a paucity of knowledge concerning how people with heart failure experience differences between specialised heart failure clinics and primary healthcare in Sweden. This study aimed to describe differences regarding information and follow- up in heart failure clinics and primary healthcare. The study was conducted in Sweden in 2011. Four people (three men, one woman: aged 60 to 84) with heart failure (NYHA II) were interviewed. The interviews were analysed with qualitative content analysis. The findings revealed after referral from the heart failure clinic to primary healthcare, follow-ups were omitted. Still, the patients needed care, support and information. The findings are illuminated in four themes. The patients' varying and individual needs can be difficult to recognise and manage unless they are followed-up from either HFC or PHC on a regular basis.
|
|
| 5. |
- Andersson, Lena, et al.
(author)
-
Differences between heart failure clinics and primary health care regarding information and follow-up
- 2013
-
In: British Journal of Community Nursing. - : Mark Allen Group. - 1462-4753 .- 2052-2215. ; 18:6, s. 288-292
-
Journal article (peer-reviewed)abstract
- There is a paucity of knowledge concerning how people with heart failure experience differences between specialised heart failure clinics and primary healthcare in Sweden. This study aimed to describe differences regarding information and followup in heart failure clinics and primary healthcare. The study was conducted in Sweden in 2011. Four people (three men, one woman; aged 60 to 84) with heart failure (NYHA II) were interviewed. The interviews were analysed with qualitative content analysis. The findings revealed after referral from the heart failure clinic to primary healthcare, follow-ups were omitted. Still, the patients needed care, support and information. The findings are illuminated in four themes. The patients' varying and individual needs can be difficult to recognise and manage unless they are followed-up from either HFC or PHC on a regular basis.
|
|
| 6. |
- Andreasson, Eskil, et al.
(author)
-
Integrating Moldflow and Abaqus in the Package Simulation Workflow
- 2013
-
Conference paper (peer-reviewed)abstract
- Tetra Pak has used numerical simulation tools for plastic injection molding (Moldflow) and structural analysis (Abaqus/Implicit and Abaqus/Explicit) for many years. Today these two simulation tools are used independently of each other without any coupling. How these two disciplines can be combined to better predict the mechanical response of a polymer component is presented in this work. The manufacturing process, in this case injection molding, creates the mechanical properties of the produced polymer part. Process settings, material selection and molding tool geometry affect the polymer flow, material orientation and rate of crystallinity. A method to build a layered finite element model in Abaqus using results from Moldflow simulations regarding crystallinity growth and molecular orientation is proposed. Relatively simple material models were utilized and assigned for each individual material layer through the thickness in the polymer part. These constitutive models were derived phenomenologically from experimental test results and could adequately capture both the microscopic and the macroscopic behavior in a more realistic way. The numerical results showed a good agreement with the experimental results, both regarding visual appearance and force/displacement response.
|
|
| 7. |
|
|
| 8. |
- Bolte, S., et al.
(author)
-
The Roots of Autism and ADHD Twin Study in Sweden (RATSS)
- 2014
-
In: Twin Research and Human Genetics. - Stockholm : Cambridge University Press (CUP). - 1832-4274 .- 1839-2628. ; 17:3, s. 164-176
-
Journal article (peer-reviewed)abstract
- Neurodevelopmental disorders affect a substantial minority of the general population. Their origins are still largely unknown, but a complex interplay of genetic and environmental factors causing disturbances of the central nervous system's maturation and a variety of higher cognitive skills is presumed. Only limited research of rather small sample size and narrow scope has been conducted in neurodevelopmental disorders using a twin-differences design. The Roots of Autism and ADHD Twin Study in Sweden (RATSS) is an ongoing project targeting monozygotic twins discordant for categorical or dimensional autistic and inattentive/hyperactive-impulsive phenotypes as well as other neurodevelopmental disorders, and typically developing twin controls. Included pairs are 9 years of age or older, and comprehensively assessed for psychopathology, medical history, neuropsychology, and dysmorphology, as well as structural, functional, and molecular brain imaging. Specimens are collected for induced pluripotent (iPS) and neuroepithelial stem cells, genetic, gut bacteria, protein-/monoamine, and electron microscopy analyses. RATSS's objective is to generate a launch pad for novel surveys to understand the complexity of genotype-environment-phenotype interactions in autism spectrum disorder and attention-deficit hyperactivity disorder (ADHD). By October 2013, RATSS had collected data from 55 twin pairs, among them 10 monozygotic pairs discordant for autism spectrum disorder, seven for ADHD, and four for other neurodevelopmental disorders. This article describes the design, recruitment, data collection, measures, collected pairs' characteristics, as well as ongoing and planned analyses in RATSS. Potential gains of the study comprise the identification of environmentally mediated biomarkers, the emergence of candidates for drug development, translational modeling, and new leads for prevention of incapacitating outcomes.
|
|
| 9. |
|
|
| 10. |
|
|
